VIPOC Represented at the German Dermatological Society
The 52nd conference of the German Dermatological Society (DDG) was…
Incyte Announces European Commission Approval Of Opzelura® (Ruxolitinib) Cream For The Treatment Of Non-Segmental Vitiligo With Facial Involvement In Adults And Adolescents
April 20, 2023 at 10:21 AM EDT Opzelura® (ruxolitinib) Cream is…
Body Care Tips for Vitiligo Patients
4 April 2023
Body Care Tips for Vitiligo Patients
Vitiligo is a condition that causes the loss of skin…
The first step for a medicinal product for vitiligo has been authorized in Europe
On February 23, 2023, the European Medicines Agency (EMA) published…
Current Status of Cell-Based Therapies for Vitiligo
23 February 2023
Current Status of Cell-Based Therapies for Vitiligo
Abstract Vitiligo is a chronic pigmentary disease with complex etiology,…
Types of Sun Protective Clothing
23 February 2023
Types of Sun Protective Clothing
It's important for vitiligo patients to protect their skin from…
Protecting Against UVA Rays in the Car
23 February 2023
Protecting Against UVA Rays in the Car
People with vitiligo may be concerned about protecting their skin…
Good news from the Franco-Congolese Vitiligo Association our newest VIPOC member
With a lot of energy and willpower, The President,…
Vitiligo in Children: A Review of Conventional Treatments
25 January 2023
Vitiligo in Children: A Review of Conventional Treatments
Introduction Vitiligo is an acquired, chronic, maybe autoimmune, pigmentary disorder…
